7 Best Stocks for the Next 30 Days

Get them in a free Special Report, and get more Zacks Insights in our free e-newsletter, Profit from the Pros. Every issue includes a fresh Zacks #1 Bull Stock of the Day.

Privacy Policy
Close This Panel X
  • Latest News
  • Most Popular
View All | Scroll Down Scroll Up

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Recent Quotes

No Recent Quote currently available

My Portfolio

My Portfolio Tracker

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Stocks on the Move 05/21/2013

Company Name Symbol %Change
SCIENTIFIC L SCIL
8.00%
NATUS MEDICA BABY
6.11%
SUMMER INFAN SUMR
6.02%
RADIANT LOGI RLGT
5.32%
NEW ORIENTAL EDU
4.51%

Zacks Rank #1 Strong Buys

Analyst Blog

Print
Share

Accuray Down to Underperform

by Zacks Equity Research

November 28, 2012 | Comments : 0 Recommended this article: (0)

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Following its disappointing first quarter fiscal 2013 results, we are downgrading our recommendation on Accuray Incorporated ( ARAY - Analyst Report ) to ‘Underperform’ with a price target of $6.

The company’s adjusted loss per share of 23 cents was wider than the Zacks Consensus Estimate of a loss of 20 cents in the reported quarter. Moreover, adjusted revenues of $83 million (down 13.3% year-over-year), also trailed the Zacks Consensus Estimate of $87 million.
Further, we remain concerned about the declining Cyberknife sales. Net orders for the CyberKnife products dropped 12% in the quarter. Accuray is totally dependent on the CyberKnife and TomoTherapy systems sales for its long-term profitability. Hence, any disruptions to the sales of these products will lead to a loss of customers, which will be unfavorable to top-line growth.
Moreover, margin contraction is also a major cause of concern for the company. Adjusted gross margin for the quarter was 33.3% versus 36.4% in the year-ago quarter, due to change in sales mix. Additionally, adjusted operating loss was $17.7 million compared with a loss of $9.9 million, a year ago.
Accuray remains susceptible to the weak U.S. and European markets and reimbursement uncertainties. It also faces stiff challenges from competitive product offerings of Varian Medical Systems Inc. ( VAR - Analyst Report ) and Integra LifeSciences Holdings Corporation ( IART - Snapshot Report ) .
Despite these shortcomings, we must take into account that Accuray is a renowned supplier of radiosurgery offerings and provides non-surgical treatment option for patients diagnosed with cancer. Globally, more than 200,000 people have been treated with the company’s technology.
We are upbeat about the compelling prospect in radiation oncology rendered by the TomoTherapy acquisition. New products are expected to drive long-term growth for the company. In addition, Acurray is focusing on investing in emerging markets to expand its business.
The stock carries a short-term Zacks #3 Rank (Hold rating).

Read the full Analyst Report on VAR

Read the full Snapshot Report on IART

Read the full Analyst Report on ARAY

Email Print Share Rate Pos Rate Neg

Disclosure / Disclaimer Link
Read/Post Comments (0) | Recommended this article (0)

Please login to Zacks.com or register to post a comment.
Quick Links

Services

My Account

Resources

Client Support

Follow Us

Facebook

Twitter

Linkedin

RSS

You Tube

Zacks Research is Reported On:

Zacks Investment Research

is an A+ Rated BBB

Accredited Business.

Copyright 2013 Zacks Investment Research

At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.

Visit performance for information about the performance numbers displayed above.

NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.